Literature DB >> 30523709

Initial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists and American Society of Hematology Guideline.

Valérie de Haas1, Nofisat Ismaila2, Anjali Advani3, Daniel A Arber4, Raetasha S Dabney5, Dipti Patel-Donelly6, Elizabeth Kitlas7, Rob Pieters1, Ching-Hon Pui8, Kendra Sweet9, Ling Zhang9.   

Abstract

PURPOSE: The College of American Pathologists (CAP) and the American Society of Hematology (ASH) developed an evidence-based guideline on the initial diagnostic work-up of acute leukemia (AL). Because of the relevance of this topic to the ASCO membership, ASCO reviewed the guideline and applied a set of procedures and policies for endorsing clinical practice guidelines that have been developed by other professional organizations.
METHODS: The CAP-ASH guideline on initial diagnostic work-up of AL was reviewed for developmental rigor by methodologists. Then, an ASCO Endorsement Expert Panel updated the literature search and reviewed the content and recommendations.
RESULTS: The ASCO Expert Panel determined that the recommendations from the guideline, published in 2016, are clear, thorough, and based on the most relevant scientific evidence. ASCO fully endorsed the CAP-ASH guideline on initial diagnostic work-up of AL and included some discussion points according to clinical practice and updated literature.
CONCLUSION: Twenty-seven guideline statements were reviewed. Some discussion points were included to better assess CNS involvement in leukemia and to provide novel insights into molecular diagnosis and potential markers for risk stratification and target therapy. These discussions are categorized into four sections: (1) initial diagnosis focusing on basic diagnostics and determination of risk parameters, (2) molecular markers and minimal residual disease detection, (3) context of referral to another institution with expertise in the management of AL, and (4) reporting and record keeping for better outlining and follow-up discussion. Additional information is available at: www.asco.org/hematologic-malignancies-guidelines .

Entities:  

Mesh:

Year:  2018        PMID: 30523709      PMCID: PMC6338392          DOI: 10.1200/JCO.18.01468

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  63 in total

1.  Core-binding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002/01 trial: screening and prognostic impact of c-KIT mutations.

Authors:  E Manara; V Bisio; R Masetti; V Beqiri; R Rondelli; G Menna; C Micalizzi; N Santoro; F Locatelli; G Basso; M Pigazzi
Journal:  Leukemia       Date:  2013-11-14       Impact factor: 11.528

2.  Deregulation of DUX4 and ERG in acute lymphoblastic leukemia.

Authors:  Jinghui Zhang; Kelly McCastlain; Hiroki Yoshihara; Beisi Xu; Yunchao Chang; Michelle L Churchman; Gang Wu; Yongjin Li; Lei Wei; Ilaria Iacobucci; Yu Liu; Chunxu Qu; Ji Wen; Michael Edmonson; Debbie Payne-Turner; Kerstin B Kaufmann; Shin-Ichiro Takayanagi; Erno Wienholds; Esmé Waanders; Panagiotis Ntziachristos; Sofia Bakogianni; Jingjing Wang; Iannis Aifantis; Kathryn G Roberts; Jing Ma; Guangchun Song; John Easton; Heather L Mulder; Xiang Chen; Scott Newman; Xiaotu Ma; Michael Rusch; Pankaj Gupta; Kristy Boggs; Bhavin Vadodaria; James Dalton; Yanling Liu; Marcus L Valentine; Li Ding; Charles Lu; Robert S Fulton; Lucinda Fulton; Yashodhan Tabib; Kerri Ochoa; Meenakshi Devidas; Deqing Pei; Cheng Cheng; Jun Yang; William E Evans; Mary V Relling; Ching-Hon Pui; Sima Jeha; Richard C Harvey; I-Ming L Chen; Cheryl L Willman; Guido Marcucci; Clara D Bloomfield; Jessica Kohlschmidt; Krzysztof Mrózek; Elisabeth Paietta; Martin S Tallman; Wendy Stock; Matthew C Foster; Janis Racevskis; Jacob M Rowe; Selina Luger; Steven M Kornblau; Sheila A Shurtleff; Susana C Raimondi; Elaine R Mardis; Richard K Wilson; John E Dick; Stephen P Hunger; Mignon L Loh; James R Downing; Charles G Mullighan
Journal:  Nat Genet       Date:  2016-10-24       Impact factor: 38.330

3.  Race/ethnicity and the risk of childhood leukaemia: a case-control study in California.

Authors:  Sona Oksuzyan; Catherine M Crespi; Myles Cockburn; Gabor Mezei; Ximena Vergara; Leeka Kheifets
Journal:  J Epidemiol Community Health       Date:  2015-03-19       Impact factor: 3.710

4.  Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.

Authors:  Jessica A Pollard; Todd A Alonzo; Robert B Gerbing; Phoenix A Ho; Rong Zeng; Yaddanapudi Ravindranath; Gary Dahl; Norman J Lacayo; David Becton; Myron Chang; Howard J Weinstein; Betsy Hirsch; Susana C Raimondi; Nyla A Heerema; William G Woods; Beverly J Lange; Craig Hurwitz; Robert J Arceci; Jerald P Radich; Irwin D Bernstein; Michael C Heinrich; Soheil Meshinchi
Journal:  Blood       Date:  2010-01-07       Impact factor: 22.113

5.  Breakpoint-specific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia.

Authors:  Aurélie Caye; Kheïra Beldjord; Kelly Mass-Malo; Séverine Drunat; Jean Soulier; Virginie Gandemer; André Baruchel; Yves Bertrand; Hélène Cavé; Emmanuelle Clappier
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

Review 6.  The importance of FLT3 mutational analysis in acute myeloid leukemia.

Authors:  Mrinal M Patnaik
Journal:  Leuk Lymphoma       Date:  2017-11-22

7.  IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951.

Authors:  E Clappier; N Grardel; M Bakkus; J Rapion; B De Moerloose; P Kastner; A Caye; J Vivent; V Costa; A Ferster; P Lutz; F Mazingue; F Millot; D Plantaz; G Plat; E Plouvier; M Poirée; N Sirvent; A Uyttebroeck; K Yakouben; S Girard; N Dastugue; S Suciu; Y Benoit; Y Bertrand; H Cavé
Journal:  Leukemia       Date:  2015-06-08       Impact factor: 11.528

8.  Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.

Authors:  Cecile Bally; Lionel Adès; Aline Renneville; Marie Sebert; Virginie Eclache; Claude Preudhomme; Marie-Joelle Mozziconacci; Hugues de The; Jacqueline Lehmann-Che; Pierre Fenaux
Journal:  Leuk Res       Date:  2014-03-23       Impact factor: 3.156

Review 9.  Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance.

Authors:  David Grimwade; Adam Ivey; Brian J P Huntly
Journal:  Blood       Date:  2015-12-10       Impact factor: 25.476

10.  Detection of prognostically relevant mutations and translocations in myeloid sarcoma by next generation sequencing.

Authors:  Karl Kashofer; Max Gornicec; Karin Lind; Veronica Caraffini; Silvia Schauer; Christine Beham-Schmid; Albert Wölfler; Gerald Hoefler; Heinz Sill; Armin Zebisch
Journal:  Leuk Lymphoma       Date:  2017-06-20
View more
  5 in total

Review 1.  Technological features of blast identification in the cerebrospinal fluid: A systematic review of flow cytometry and laboratory haematology methods.

Authors:  John L Frater; Cara Lunn Shirai; Jonathan R Brestoff
Journal:  Int J Lab Hematol       Date:  2022-07-04       Impact factor: 3.450

Review 2.  KMT2A-ARHGEF12, a therapy related fusion with poor prognosis.

Authors:  Nada Assaf; Raphael Liévin; Fatiha Merabet; Victoria Raggueneau; Jenifer Osman; Rathana Kim; Francine Garnache; Mariella D'Angiò; Patrizia Larghero; Claus Meyer; Rolf Marschalek; Philippe Rousselot; Christine Terré
Journal:  Mol Biol Rep       Date:  2021-08-12       Impact factor: 2.742

3.  The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia.

Authors:  Michael M Boyiadzis; Ivan Aksentijevich; Daniel A Arber; John Barrett; Renier J Brentjens; Jill Brufsky; Jorge Cortes; Marcos De Lima; Stephen J Forman; Ephraim J Fuchs; Linda J Fukas; Steven D Gore; Mark R Litzow; Jeffrey S Miller; John M Pagel; Edmund K Waller; Martin S Tallman
Journal:  J Immunother Cancer       Date:  2020-10       Impact factor: 13.751

4.  Evaluation of reporting quality in clinical practice guidelines for acute myeloid leukemia using the RIGHT checklist.

Authors:  Ding Li; Cheng Cheng; Ziming Wang; Yi Zhang; Dongbei Li; Wenping Song; Baoxia He; Xuan Wu; Wenzhou Zhang
Journal:  Ann Transl Med       Date:  2021-09

5.  Clinical Impact of Measurable Residual Disease in Acute Myeloid Leukemia.

Authors:  Tali Azenkot; Brian A Jonas
Journal:  Cancers (Basel)       Date:  2022-07-26       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.